GCP
VRDN icon

GSA Capital Partners’s Viridian Therapeutics VRDN Stock Holding History

GSA Capital Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,771
Closed -$802K – 2198
2025
Q4 		$802K Buy
+25,771
New +$707K 0.07% 487
2025
Q1 		– Sell
-11,332
Closed -$217K – 2108
2024
Q4 		$217K Buy
+11,332
New +$246K 0.02% 1374
2023
Q4 		– Sell
-10,844
Closed -$166K – 1972
2023
Q3 		$166K Buy
+10,844
New +$207K 0.01% 1321
2020
Q4 		– Sell
-1,288
Closed -$15K – 1633
2020
Q3 		$15K Buy
+1,288
New +$19.2K ﹤0.01% 1218

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return